In ₹ Crore except Per Share Latest Annual | NATCOPHARM FY26 | DRREDDY FY26 | ZYDUSLIFE FY26 | SUNPHARMA FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 10.34× | 22.63× | 22.33× | 38.70× | 22.63× -54% | |
| P/B | ◆ 1.59× | 2.49× | 3.80× | 5.29× | 3.80× -58% | |
| EV/EBITDA | ◆ 10.15× | 14.91× | 13.88× | 23.53× | 14.91× -32% | |
| Market Cap | ₹14,657 Cr | ₹95,274 Cr | ₹1.13L Cr | ₹4.44L Cr | ₹1.13L Cr -87% | |
| Growth | ||||||
| Revenue CAGR 3Y | 14.64% | 10.96% | ◆ 16.35% | 10.03% | 10.96% +34% | |
| Revenue CAGR 5Y | ◆ 14.72% | 12.09% | 12.45% | 11.78% | 12.09% +22% | |
| Net Income CAGR 3Y | 25.64% | -2.66% | ◆ 34.80% | 10.57% | 10.57% +143% | |
| Revenue YoY (latest Q) | -44.68% | -5.51% | ◆ 21.96% | 10.46% | 10.46% -527% | |
| Net Income YoY (latest Q) | -57.01% | -69.10% | -34.90% | ◆ 26.53% | -34.90% -63% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 35.22% | 19.15% | 31.22% | 30.33% | 30.33% +16% | |
| Net Income Margin | ◆ 34.78% | 12.34% | 18.87% | 19.69% | 18.87% +84% | |
| Return on Common Equity | 15.38% | 10.98% | ◆ 17.04% | 13.69% | 13.69% +12% | |
| Return on Capital Employed | 13.09% | 10.62% | ◆ 19.26% | 17.17% | 17.17% -24% | |
| Return on Assets | ◆ 12.81% | 7.15% | 9.78% | 10.58% | 9.78% +31% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.08× | 0.16× | 0.40× | ◆ 0.05× | 0.16× -50% | |
| Interest Coverage | 33.51× | 11.76× | 16.10× | ◆ 43.65× | 16.10× +108% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹4,078 Cr | ₹33,700 Cr | ₹27,148 Cr | ₹58,462 Cr | ₹33,700 Cr -88% | |
| Net Income | ₹1,419 Cr | ₹4,158 Cr | ₹5,124 Cr | ₹11,509 Cr | ₹5,124 Cr -72% | |
| Total Assets | ₹11,074 Cr | ₹58,123 Cr | ₹52,407 Cr | ₹1.09L Cr | ₹58,123 Cr -81% | |
| EPS | ₹79.2 | ₹50.41 | ₹50.09 | ₹47.8 | ₹50.09 +58% | |
| Book Value per Share | ₹515.15 | ₹457.86 | ₹294.06 | ₹349.6 | ₹349.6 +47% | |